Last $38.21 USD
Change Today +0.38 / 1.00%
Volume 177.2K
ANIK On Other Exchanges
As of 12:14 PM 09/23/14 All times are local (Market data is delayed by at least 15 minutes).

anika therapeutics inc (ANIK) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/26/14 - $52.49
52 Week Low
10/8/13 - $23.26
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

anika therapeutics inc (ANIK) Related Businessweek News

No Related Businessweek News Found

anika therapeutics inc (ANIK) Details

Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair in the United States, Europe, and internationally. The company’s products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, and MONOVISC for the treatment of osteoarthritis of the knee and joints; Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells that is used in connection with soft tissue regeneration; Hyalonect, a woven gauze used as a graft wrap; Hyaloss used to mix blood/bone grafts to form a paste for bone regeneration; and Hyaloglide, an ACP gel used in tenolysis treatment. The company’s dermal products include wound care products that comprise Hyalomatrix and Hyalofill, for treatment of complex wounds, such as burns and ulcers; Hyalograft 3D and Laserskin scaffolds for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise Hyalobarrier, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product for the prevention of spinal post-surgical adhesions; Merogel, a woven fleece nasal packin; and Merogel Injectable, a viscous hydrogel. The company’s ophthalmic products include AMVISC, AMVISC Plus, STAARVISC-II, Optivisc, AnikaVisc, and AnikaVisc Plus that are injectable HA products used as viscoelastic agents in ophthalmic surgical procedures, including cataract extraction and intraocular lens implantation; and veterinary product comprise HYVISC, an injectable HA product used for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. markets its products through a network of distributors. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

102 Employees
Last Reported Date: 03/13/14
Founded in 1983

anika therapeutics inc (ANIK) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $400.9K
Chief Commercial Officer
Total Annual Compensation: $452.8K
Chief Scientific Officer
Total Annual Compensation: $116.7K
Compensation as of Fiscal Year 2013.

anika therapeutics inc (ANIK) Key Developments

Anika Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Second Half and Year 2014

Anika Therapeutics Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of $26,274,660 compared to $20,828,377 a year ago. Income from operations was $15,202,713 compared to $9,398,492 a year ago. Income before income taxes was $15,208,648 compared to $9,362,111 a year ago. Net income was $9,302,350 compared to $5,894,892 a year ago. Diluted net income per share was $0.60 compared to $0.40 a year ago. For the six months, the company reported total revenue of $60,284,947 compared to $36,075,388 a year ago. Income from operations was $39,073,281 compared to $14,409,916 a year ago. Income before income taxes was $39,079,683 compared to $14,333,977 a year ago. Net income was $24,332,603 compared to $8,962,894 a year ago. Diluted net income per share was $1.57 compared to $0.62 a year ago. The company continues to expect product revenue will grow significantly higher during the second half of year 2014. The company expects to achieve product revenue growth for 2014 in the high-teens range with at least equivalent net income and EPS growth. Product gross margin for the full year to be around the high 68 percentage range.

Anika Therapeutics Announces U.S. Commercialization Partnership for Hyalomatrix(R) with Wound Care Leader Medline Industries, Inc

Anika Therapeutics, Inc. announced that it has entered into a new agreement with Medline Industries, Inc. to commercialize the company's advanced wound care product - Hyalomatrix(R), in the United States on an exclusive basis through 2019. Anika will receive product payment and royalty revenues from the sale of the product by Medline. Hyalomatrix(R) is a biologically-derived matrix for in-growing cells, and has the U.S. Food and Drug Administration marketing clearance. Medline is the privately held manufacturer and distributor of healthcare products and services in the United States, and has more than 1,200 dedicated sales representatives to support its broad product line. With an extensive team of clinical consultants and product experts, Medline is at the forefront of providing comprehensive wound care solutions to healthcare providers across the continuum of care.

Anika Therapeutics Inc. to Report Q2, 2014 Results on Jul 30, 2014

Anika Therapeutics Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Jul 30, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANIK:US $38.21 USD +0.38

ANIK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Iridex Corp $7.10 USD -0.20
STAAR Surgical Co $11.18 USD -0.07
View Industry Companies

Industry Analysis


Industry Average

Valuation ANIK Industry Range
No financial data is available for ANIK.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANIKA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at